PMID- 8725877
OWN - NLM
STAT- MEDLINE
DCOM- 19961108
LR  - 20121115
IS  - 0929-1903 (Print)
IS  - 0929-1903 (Linking)
VI  - 3
IP  - 3
DP  - 1996 May-Jun
TI  - Transduction of human renal carcinoma cells with human gamma-interferon gene via 
      retroviral vector.
PG  - 143-50
AB  - We used a retroviral vector containing a human gamma-interferon (gamma-IFN) gene 
      to transduce 13 renal carcinoma cell lines. The transduction efficiencies ranged 
      from 0% to 60%, as determined by using an analogous vector containing the LacZ 
      marker gene. In addition, gene-transferred resistance to the antibiotic neomycin 
      was used to select for transduced cells. Nine of 13 lines were successfully 
      transduced. Transduction was associated with the morphologic change of 
      elongation, and there was a marked decrease in cell growth rate. Transduced cells 
      secreted varying amounts (20-1076 pg/10(6) cells/d) of gamma-IFN as measured by 
      enzyme-linked immunosorbent assay for at least 2 to 3 weeks after transduction 
      (including 1 day of transduction, 6-7 days of selection, and an additional 8-12 
      days before the first passage of the transduced cells). Human leukocyte antigen 
      (HLA) class II expression was markedly increased in six of seven cell lines; HLA 
      class I expression was significantly increased in two of eight lines. Transduced 
      cells that were subjected to cryopreservation after irradiation still produced 
      gamma-IFN and expressed HLA class I and II antigens, although generally at lower 
      levels than before these manipulations. This study confirms that retroviral 
      vector transduction of the human gamma-IFN gene into renal carcinoma cells is 
      feasible and associated with persistent production of gamma-IFN and increased 
      expression of HLA class I and II molecules, and these effects are retained after 
      irradiation and cryopreservation. This suggests that an autologous tumor cell 
      vaccine trial with irradiated gamma-IFN gene-transduced renal carcinoma cell is 
      rationale and feasible.
FAU - Nayak, S K
AU  - Nayak SK
AD  - Cell Biology Laboratory, Hoag Cancer Center, Newport Beach, CA 92663, USA.
FAU - McCallister, T
AU  - McCallister T
FAU - Han, L J
AU  - Han LJ
FAU - Gangavalli, R
AU  - Gangavalli R
FAU - Barber, J
AU  - Barber J
FAU - Dillman, R O
AU  - Dillman RO
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Cancer Gene Ther
JT  - Cancer gene therapy
JID - 9432230
RN  - 0 (HLA-D Antigens)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (Recombinant Fusion Proteins)
RN  - 0 (Recombinant Proteins)
RN  - 82115-62-6 (Interferon-gamma)
SB  - IM
MH  - Carcinoma, Renal Cell
MH  - Cell Division
MH  - Cell Line
MH  - Cryopreservation
MH  - Genes, Reporter
MH  - Genetic Therapy/methods
MH  - Genetic Vectors
MH  - HLA-D Antigens/biosynthesis
MH  - Histocompatibility Antigens Class I/biosynthesis
MH  - Humans
MH  - Interferon-gamma/*biosynthesis
MH  - Kidney Neoplasms
MH  - Kinetics
MH  - Recombinant Fusion Proteins/biosynthesis
MH  - Recombinant Proteins
MH  - Retroviridae
MH  - Transfection/*methods
MH  - Transformation, Genetic
MH  - Tumor Cells, Cultured
EDAT- 1996/05/01 00:00
MHDA- 1996/05/01 00:01
CRDT- 1996/05/01 00:00
PHST- 1996/05/01 00:00 [pubmed]
PHST- 1996/05/01 00:01 [medline]
PHST- 1996/05/01 00:00 [entrez]
PST - ppublish
SO  - Cancer Gene Ther. 1996 May-Jun;3(3):143-50.